The landscape of genomic medicine is undergoing rapid transformation. According to a survey of hundreds of healthcare leaders conducted for GlobalData’s “State of the Biopharmaceutical Industry in 2024” report, genomics represents the most impactful industry trend for the coming year — building on momentum from previous years, and beating other major themes like decentralized trials and medical marijuana.[1]
Genomic research isn’t going anywhere, and its potential is yet to be fully realized. Increased prevalence of chronic illnesses, plummeting costs of DNA sequencing and growing funding for genomics are all helping related treatments to thrive. For example, GlobalData’s Sales and Consensus database shows the market for DNA- and RNA-based gene therapies for oncology — the largest single area of research — has been steadily increasing. It was valued at $1.4 billion in 2022, grew to $2.3 billion in 2023, and is forecast to reach $28 billion by 2029 at a CAGR of 52.3%.[2]
Behind these headlines, researchers and biopharmaceutical companies are pioneering new approaches to address some of the most challenging disease areas. Advances in multi-modal therapeutic approaches, for example, are rapidly ramping up.
In a recent discussion, Dr. Aravind Asokan, synthetic virologist and Professor at Duke University, and Clive Glover, Viral Vector Business Leader at Cytiva (now leading Cytiva’s Pall Medical business), dove into the benefits of multi-modality, analyzed some of the most exciting examples currently being tested, and talked about the benefits of industry and academic collaboration. The Promise of Multi-Modality Therapeutics
What makes the genomic medicine space so interesting right now is that modalities are quickly converging to open the doors to exciting new therapeutic possibilities.
While lentiviral vectors remain the preferred choice for gene delivery in CAR T workflows, cell therapy researchers are also looking to non-viral technologies, such as electroporation and lipid nanoparticles (LNPs). Why are these alternatives garnering interest? Following the success of COVID-19 vaccines, LNPs, for example, are considered to be a clinically validated, market-ready, and cost-effective delivery option for nucleic acids. They’re scalable and can transfect many cells with high viability and yield, while offering a favorable overall safety profile. Together, these advantages could enhance […]
The Genomic Medicine Revolution: Multi-Modality Approaches in Advanced Therapies
